The new plant is for the supply of clinical trial material.Glenmark Pharmaceuticals has opened a new manufacturing facility in Switzerland for supply of clinical trial material.
Glenmark Opens Manufacturing Plant in Switzerland The new plant is for the supply of clinical trial material.
Glenmark Pharmaceuticals has opened a new manufacturing facility in Switzerland for supply of clinical trial material.
The company said in a statement that Glenmark Pharmaceuticals S.A (GPSA), a wholly-owned subsidiary of the company has opened its new cGMP compliant monoclonal antibody manufacturing facility in La Chaux-de- Fonds, Switzerland. The company also said that the manufacturing facility will supplement Glenmark's existing in-house discovery and development capabilities and will supply material for clinical development.
It may be noted here that the focus for the biologics R&D centre is to develop novel biologic entities for the treatment of pain, oncologic, inflammatory and respiratory conditions.
The Glenmark biologics research centre has filed several patents since its inception around 10 years back.
Glenmark Pharmaceuticals today opened a new manufacturing facility in Switzerland for supply of clinical trial material.
Glenmark Pharmaceuticals S.A (GPSA), a wholly-owned subsidiary of the company has opened its new GMP compliant monoclonal antibody manufacturing facility in La Chaux-de- Fonds, Switzerland, Glenmark Pharma said in a statement.
"This manufacturing facility supplements Glenmark's existing in-house discovery and development capabilities and will supply material for clinical development," it added.
Glenmark Pharma Biologics-President Michael Buschle said: "We have been doing cutting edge work in the area of novel monoclonal antibodies and have several monoclonal antibody candidates & bispecific antibodies in the pipeline. The manufacturing facility would help us bring these antibodies to the clinic faster..."
An antibody is a protein produced by plasma cells that is used by the body's immune system to identify and neutralise foreign particles such as bacteria and viruses.
The focus for the biologics R&D centre is to develop novel biologic entities for the treatment of pa
in, oncologic, inflammatory and respiratory conditions, Glenmark Pharma said.
Since its inception around 10 years back, Glenmark's biologics research centre has filed several patents on novel biologic entities, it added.
"GBR 500, its most advanced candidate has been licensed to
Sanofi and is currently in Phase II development. GBR 900, a first-in-class molecule for treatment of chronic pain is currently in Phase I and GBR 830, an anti OX-40 antagonist, is scheduled to enter the clinic later this year," it said.
The Glenmark Pharma scrip was trading at Rs 539.90, down 0.03 per cent, on the BSE in the afternoon.
India's Glenmark, which is working on both novel monoclonal antibodies and biosimilars, needed more manufacturing capacity for its clinical trial work and so has brought online a new mAb manufacturing facility in Switzerland. With more mAbs and antibody-drug conjugates being developed for attacking cancers, a number of companies have undertaken expansion projects.
The Mumbai-based company has a number of mAbs in various stages of development, including bispecific antibodies, and so needed more capacity, Glenmark Biologics President Michael Buschle explained. "The manufacturing facility would help us bring these antibodies to the clinic faster and position Glenmark as a leading innovative pharmaceutical company," he said in a statement.
The manufacturing facility is in La Chaux-de-Fonds, Switzerland, where Glenmark has an integrated research center for antibody discovery and development. The new manufacturing facility will employ single-use bioreactor systems and also includes a suite for manufacturing cell banks. A Glenmark spokesman Wednesday said the company is not disclosing what it invested in the new facility, where it employs 69 people.